Provider Briefing: Compro (Prochlorperazine) Supply and Access in 2026

Prochlorperazine — marketed as Compro in the suppository formulation and formerly known as Compazine — remains an important antiemetic in clinical practice. As a first-generation phenothiazine antipsychotic, it's been a mainstay for severe nausea and vomiting management across emergency medicine, oncology, neurology, and primary care for decades.

However, availability challenges have become a recurring concern. This briefing provides prescribers with an up-to-date summary of the supply situation, clinical implications, therapeutic alternatives, and practical tools for ensuring patient access to Compro and its equivalents in 2026.

Supply Timeline: How We Got Here

Prochlorperazine supply disruptions have been an intermittent problem for several years:

• Injectable shortages have been the most persistent, appearing on the ASHP Drug Shortages list multiple times due to manufacturing complexities associated with sterile dosage forms.
• Oral formulations (5 mg and 10 mg tablets) have experienced periodic but generally short-lived supply gaps, primarily driven by distributor-level inventory management rather than true manufacturing shortages.
• Suppository formulations (Compro) have been subject to intermittent availability issues tied to the limited number of manufacturers — primarily Padagis US LLC — and the niche nature of the dosage form.

The pattern is consistent with broader trends in generic drug supply. According to ASHP, the number of active drug shortages has remained above 200 since 2023, with older generic injectables and specialty formulations disproportionately affected.

Current Status (Early 2026)

As of early 2026, prochlorperazine is not listed on the FDA's active drug shortage database in any formulation. However, providers and patients continue to report real-world difficulty locating the suppository form at retail pharmacies. Key observations:

• Chain pharmacies frequently do not stock Compro suppositories as a routine inventory item
• Independent pharmacies report better ability to source the product through secondary distributors
• The injectable form has stabilized but remains on backorder with some distributors
• Oral tablets are generally available without significant delays

Prescribing Implications

The availability picture has several practical implications for prescribing:

Formulation-Specific Considerations

When prescribing prochlorperazine, consider which formulation your patient can actually obtain:

• Oral tablets (5 mg, 10 mg) — most widely available; appropriate for patients who can tolerate oral medications
• Suppositories (25 mg) — essential for patients with active vomiting who cannot take oral medications; may require pharmacy-level sourcing effort
• Injectable (5 mg/mL) — primarily institutional use; availability varies by facility and distributor

When Suppositories Are Clinically Necessary

The suppository formulation serves a distinct clinical niche. Patients most likely to need it include:

• Those with active, severe vomiting who cannot retain oral medications
• Post-surgical patients transitioning from IV to non-oral antiemetics
• Cancer patients on emetogenic chemotherapy regimens who need home antiemetic coverage
• Migraine patients with severe nausea who can't tolerate oral intake

For these patients, proactively confirming pharmacy availability before prescribing — or directing them to availability tools — can prevent treatment gaps.

The Availability Picture: What Pharmacies Are Seeing

Based on reports from pharmacy networks and patient feedback:

• CVS, Walgreens, Rite Aid — may carry generic prochlorperazine tablets but often do not routinely stock suppositories
• Independent pharmacies — more likely to carry or be willing to special-order suppositories from multiple wholesale distributors
• Hospital pharmacies — generally maintain stock of all formulations but availability varies with system-level purchasing contracts
• Compounding pharmacies — can prepare prochlorperazine suppositories as a compounded preparation when commercial products are unavailable

Cost and Access Considerations

Cost is a relevant factor, particularly for uninsured or underinsured patients:

Current Pricing (Without Insurance)

• Prochlorperazine oral tablets (30 ct, 10 mg): $15 to $50 retail; as low as $3 to $16 with coupon cards (GoodRx, SingleCare)
• Compro brand suppositories (12 ct, 25 mg): $80 to $175 retail
• Generic prochlorperazine suppositories (12 ct, 25 mg): $27 to $80 with coupons

Insurance Coverage

Prochlorperazine is covered on most commercial, Medicaid, and Medicare Part D formularies as a generic. Key coverage characteristics:

• Prior authorization: Generally not required for oral or rectal formulations
• Step therapy: Not typically required
• Tier placement: Usually Tier 1 (preferred generic) with copays of $0 to $15

Patient Assistance

No active manufacturer savings or copay card programs exist for prochlorperazine (brands Compazine and Compro have no current manufacturer coupons since the drug is generic). Third-party resources include:

• NeedyMeds (needymeds.org) — database of patient assistance programs
• RxAssist (rxassist.org) — comprehensive directory of assistance programs
• Coupon cards — SingleCare, GoodRx, and RxSaver can reduce costs significantly for uninsured patients

Therapeutic Alternatives

When prochlorperazine is unavailable, consider these evidence-based alternatives:

• Ondansetron (Zofran) — 5-HT3 antagonist; first-line for many types of nausea/vomiting; available as ODT for patients who can't swallow; lower risk of extrapyramidal symptoms
• Promethazine (Phenergan) — phenothiazine class; available as suppository (closest suppository substitute); more sedating
• Metoclopramide (Reglan) — dopamine antagonist with prokinetic effects; FDA boxed warning for tardive dyskinesia with use beyond 12 weeks
• Granisetron (Kytril/Sancuso) — 5-HT3 antagonist; particularly for chemotherapy-induced nausea; transdermal patch option available

For patients who specifically need the suppository route, promethazine suppositories represent the most direct substitute. For patients who can use non-rectal routes, ondansetron ODT offers an effective alternative that dissolves on the tongue without requiring swallowing.

Tools and Resources for Providers

Several tools can help you and your patients navigate availability challenges:

• Medfinder for Providers — real-time pharmacy availability search to help patients locate Compro and other medications in stock near them
• ASHP Drug Shortages Center (ashp.org/drug-shortages) — current shortage listings and management recommendations
• FDA Drug Shortages Database (accessdata.fda.gov/scripts/drugshortages) — official shortage status and manufacturer updates

Looking Ahead

The structural factors behind prochlorperazine supply challenges — limited manufacturers, low profit margins, and niche formulations — are unlikely to change rapidly. However, the supply situation has stabilized relative to prior years, and awareness of the issue has improved among pharmacies and distributors.

Providers can help by:

• Proactively discussing availability with patients when prescribing Compro
• Having documented alternative regimens ready in the patient's chart
• Directing patients to tools like Medfinder for real-time pharmacy availability
• Considering prescribing oral formulations when clinically appropriate to avoid suppository supply issues

Final Thoughts

Prochlorperazine remains a clinically valuable antiemetic with a well-established safety and efficacy profile. The challenge isn't the drug itself — it's the supply chain. By staying informed about availability, having alternative prescribing strategies ready, and leveraging tools to help patients find their medications, providers can minimize the impact of ongoing supply disruptions.

For patient-facing resources on this topic, see our Compro shortage update for patients and how to find Compro in stock. For a provider-oriented guide to helping patients locate medications, read How to Help Your Patients Find Compro in Stock.